COMMUNIQUÉS West-GlobeNewswire

SafeSpace Global Corporation Partners with Kansas City Area Transportation Authority to Enhance Safety Ahead of FIFA World Cup 2026
26/06/2025
SafeSpace AI Platform to be Piloted on Seven KCATA Buses Knoxville, TN, June 26, 2025 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTC PINK: SSGC), a global leader in AI-driven safety and monitoring solutions, is [...]
Everest Medicines to Host Virtual Nephrology-Focused KOL Event on June 30, 2025
26/06/2025
Event titled “A Conversation on the Latest Results from the Ongoing Phase 1b/2a Clinical Trial of EVER001, a Next-Generation Covalent Reversible BTK Inhibitor for the Treatment of Primary Membranous Nephropathy (pMN)” [...]
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
26/06/2025
REYKJAVIK, Iceland, June 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, [...]
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
26/06/2025
REYKJAVIK, ICELAND (June 26, 2025) — Alvotech (NASDAQ: ALVO, ALVO SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today [...]
World No. 1 Tennis Star Aryna Sabalenka Joins Prenetics’ IM8 Health as Global Ambassador and Shareholder
26/06/2025
Aryna Sabalenka becomes first-ever current athlete shareholder in Prenetics, listed on the NASDAQ: (PRE) In just six months, IM8 is one of the fastest growing supplement brands in the world, generating an extraordinary [...]
I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
26/06/2025
71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study Responses observed in patients with low PD-L1 [...]
ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease
26/06/2025
ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per target ProFound to leverage its ProFoundry™ Platform to mine the expanded proteome to [...]
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
26/06/2025
Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity Safety profile consistent with previous clinical trials and no treatment-related serious adverse [...]
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
26/06/2025
TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of [...]
Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights
26/06/2025
Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA ® at medical [...]
Valneva annonce un accord exclusif avec CSL Seqirus pour le marketing et la distribution de ses vaccins en Allemagne
26/06/2025
Saint-Herblain, France, le 26 juin 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui un accord exclusif avec CSL Seqirus, l'une des plus grandes [...]
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
26/06/2025
Saint-Herblain, France, June 26, 2025 – Valneva SE , (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world’s largest influenza [...]
26 ZAZA THCA Flower Strains Unleashed: The Hemp Doctor’s Largest Drop Yet
26/06/2025
MOORESVILLE, N.C., June 26, 2025 (GLOBE NEWSWIRE) -- The Hemp Doctor, America’s premier hemp and cannabinoid brand, introduces its largest THCA flower collection release with 26 indoor-grown unique strains handpicked [...]
Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women
26/06/2025
First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women. The multi-partner research project is aimed at expanding access to mpox vaccines for vulnerable populations. [...]
First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany
26/06/2025
ALK ( ALKB:DC / OMX: ALK B ) today announced the first market launch of EURneffy ® 2 mg (the trade name for neffy ® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely emergency [...]
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
26/06/2025
Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T. GAITHERSBURG, Md., June 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing [...]
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
26/06/2025
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in upfront and [...]
Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting
25/06/2025
PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant [...]
Neurosculpting Institute Announces Peer-Reviewed Study Linking Neurosculpting Meditation to Improved Clinical Accuracy in Dental Students
25/06/2025
Denver, CO , June 25, 2025 (GLOBE NEWSWIRE) -- The Neurosculpting® Institute , a meditation and neuroplasticity education organization, announced the publication of a peer-reviewed study in the Cureus Journal of Medical [...]

Pages